FIGURE 1.

(a) Chest computed tomography images of interstitial lung abnormalities. (a, b) Patients with nonfibrotic interstitial lung abnormalities. (c, d) Patients with fibrotic interstitial lung abnormalities. (b) Flow diagram of the study population. In total, 264 patients were enrolled. Of the 264 patients, 57 had interstitial lung abnormalities (ILAs); 14 had fibrotic ILAs and 43 had nonfibrotic ILAs. There were 51 patients treated with a programmed death‐1 (PD‐1) inhibitor, five treated with a programmed death‐ligand 1 (PD‐L1) inhibitor, one patient was treated with both a PD‐1 and PD‐L1 inhibitor. Of the 57 ILA patients, seven developed immune checkpoint inhibitor‐induced interstitial lung disease (ICI‐ILD); four had fibrotic ILAs and three had nonfibrotic ILAs. There were six patients treated with a PD‐1 inhibitor and one treated with a PD‐L1 inhibitor. Of the seven ILA patients with ICI‐ILD, 4 had early‐onset disease; three cases had fibrotic and one had nonfibrotic ILAs. There were three patients treated with a PD‐1 inhibitor and one treated with a PD‐L1 inhibitor